Jeong Rachel, James Matthew T, Quinn Robert R, Ravani Pietro, Bagshaw Sean M, Stelfox Henry T, Pannu Neesh, Clarke Alix, Wald Ron, Harrison Tyrone G, Niven Daniel J, Lam Ngan N
Division of Nephrology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Kidney Med. 2023 Jun 21;5(8):100685. doi: 10.1016/j.xkme.2023.100685. eCollection 2023 Aug.
RATIONALE & OBJECTIVE: To evaluate follow-up care of critically ill patients with acute kidney injury (AKI).
Retrospective cohort study.
SETTING & PARTICIPANTS: Patients admitted to the intensive care unit (ICU) with AKI in Alberta, Canada from 2005 to 2018, who survived to discharge without kidney replacement therapy or estimated glomerular filtration rate <15 mL/min/1.73 m.
AKI (defined as ≥50% or ≥0.3 mg/dL serum creatinine increase).
The primary outcome was the cumulative incidence of an outpatient serum creatinine and urine protein measurement at 3 months postdischarge. Secondary outcomes included an outpatient serum creatinine or urine protein measurement or a nephrologist visit at 3 months postdischarge.
Patients were followed from hospital discharge until the first of each outcome of interest, death, emigration from the province, kidney replacement therapy (maintenance dialysis or kidney transplantation), or end of study period (March 2019). We used non-parametric methods (Aalen-Johansen) to estimate the cumulative incidence functions of outcomes accounting for competing events (death and kidney replacement therapy).
There were 29,732 critically ill adult patients with AKI. The median age was 68 years (IQR, 57-77), 39% were female, and the median baseline estimated glomerular filtration rate was 72 mL/min/1.73 m (IQR, 53-90). The cumulative incidence of having an outpatient creatinine and urine protein measurement at 3 months postdischarge was 25% (95% CI, 25-26). At 3 months postdischarge, 64% (95% CI, 64-65) had an outpatient creatinine measurement, 28% (95% CI, 27-28) had a urine protein measurement, and 5% (95% CI, 4-5) had a nephrologist visit.
We lacked granular data, such as urine output.
Many critically ill patients with AKI do not receive the recommended follow-up care. Our findings highlight a gap in the transition of care for survivors of critical illness and AKI.
评估急性肾损伤(AKI)重症患者的后续护理情况。
回顾性队列研究。
2005年至2018年期间在加拿大艾伯塔省因AKI入住重症监护病房(ICU)且存活至出院、未接受肾脏替代治疗或估计肾小球滤过率<15 mL/min/1.73 m²的患者。
AKI(定义为血清肌酐升高≥50%或≥0.3 mg/dL)。
主要结局指标是出院后3个月门诊血清肌酐和尿蛋白测量的累积发生率。次要结局指标包括出院后3个月门诊血清肌酐或尿蛋白测量或肾病专家就诊情况。
对患者从出院开始随访,直至出现首个感兴趣的结局、死亡、移出该省、肾脏替代治疗(维持性透析或肾移植)或研究期结束(2019年3月)。我们使用非参数方法(Aalen-Johansen法)估计考虑竞争事件(死亡和肾脏替代治疗)的结局累积发生率函数。
共有29732例AKI重症成年患者。中位年龄为68岁(四分位间距,57 - 77岁);39%为女性;基线估计肾小球滤过率中位数为72 mL/min/1.73 m²(四分位间距,53 - 90)。出院后3个月进行门诊肌酐和尿蛋白测量的累积发生率为25%(95%置信区间,25 - 26)。出院后3个月,64%(95%置信区间,64 - 65)进行了门诊肌酐测量,28%(95%置信区间,27 - 28)进行了尿蛋白测量,5%(95%置信区间,4 - 5)有肾病专家就诊。
我们缺乏如尿量等详细数据。
许多AKI重症患者未接受推荐性的后续护理。我们的研究结果凸显了危重症和AKI幸存者护理过渡方面的差距。